Merkel cell carcinoma (MCC) is a rare poorly differentiated neuroendocrine tumor, usually located in sun-exposed skin, with aggressive behavior and with high recurrence risk and metastatic disease. In Latin America, case series have been published, and it does not exceed 32 patients in 10 years, and in Colombia, there are case reports. We present a descriptive retrospective cross-sectional study in patients diagnosed with MCC in the Department of Pathology and Laboratories at the University Hospital Fundación Santa Fe de Bogotá (FSFB) between January 2003 and December 2018. We present the demographic, clinical, and pathological variables of these patients, as well as a literature review.

1. Introduction

Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous malignancy with unknown cellular origin, and current information reveals a trilinear differentiation; epithelial, neuroendocrine, and early B cell lymphocytic carcinoma [1]. 5-year survival for advanced-stage MCC has been reported between 0 and 18% [1], the incidence of Merkel cell carcinoma is about 3 per 100000 worldwide, and incidences appear to be increased either due to an aging population or improved detection [2]. MCC incidence varies by geographic regions, and it ranges from 0.13 per 100000 person-years in Europe to 1.6 per 100000 person-years. It accounts for <1% of cutaneous cancers in Europe based on a retrospective cohort study with 20 diagnosed MCC cases. In Colombia and Latin America, there are some reports published; one of the biggest reports is from Carneiro et al. with 32 cases presented in a period of 10 years in the Instituto Nacional de Cancer, on which they report late diagnosis that leads to high lethality by invasive disease [3].

Many reports of case series have identified the clinical features of MCC, and typically it present as a firm, painless red-violet nodule that is dome-shaped and has undergone rapid growth [4, 5]. Nodules are common in areas exposed to sun, most frequently occur on head and neck, and less common on lower limbs, trunk, or other areas not exposed to sunlight [6]. History of extensive sun/ultraviolet (UV) exposure is recognized as a likely risk factor, and others include older age (most patients > 65 years old), Caucasian ethnicity, polyomavirus infection (reported 45%–100% of cases of MCC), and immunosuppressive states [2, 6, 7]. Some authors have described that Merkel cell polyomavirus (MCPyV) positive displayed very low mutation rates, but MCC polyomavirus negative exhibited a high mutation burden associated with a UV-induced DNA damage signature [8]. UV-induced damage is associated with the anatomic site of presentation and could differ by sex from the information of population surveillance [9].

For the definitive diagnosis, a biopsy is required; histology of MCC typically shows hyperchromatic nuclei and high mitotic activity on hematoxylin and eosin (H & E) staining. Histologic subtypes include intermediate type-most common, characterized by basophilic nuclei with high mitotic activity; trabecular type-rare usually only seen in
mixed tumors; and small cell type-undifferentiated and may be identical to small-cell carcinomas of other sites, and less common morphological subtypes include glandular, squamous, and melanocytic carcinomas [1]. An immunohistochemistry study has to be performed with the appropriated immunopanel, and cytokeratin 20 (CK-20) was reported to be positive in 89%–100% of cases of MCC and considered testing for other neuroendocrine tumor markers to exclude other differential diagnoses including chromogranin A and synaptophysin.

### 2. Materials and Methods

A retrospective review of all pathology samples with diagnosis of MCC and/or poorly differentiated neuroendocrine carcinoma in the skin was conducted in the University Hospital Fundación Santa Fe de Bogotá between January 2003 and December 2018. Approval from the Institutional Review Board was obtained before data collection. Data were extracted from the electronic medical record, and each case was compared to electronic pathology records to find pathological characteristics reported.

The medical information was reviewed and compared to the reported in the pathology database for each analyzed case, and then each pathology slide was reviewed and additional clinically relevant information was included in a medical independent database designed for this investigation. Cases found in the database and identify as repeated were excluded.

### 3. Results

A total of 36 patients included in the review during the 10 years were analyzed in our pathology lab; there were 12 men (55.6%) and 16 women (44.4%), with a median age of 68 years (range 17–87 years). Clinicopathological characteristics of MCC are shown in Table 1 and Figure 1; the head and neck were the most common locations. 41% followed by the primary site were unknown and the last was skin without other specification (8.3%). Cytokeratin 7 was positive in 2 patients (5.6%), cytokeratin 20 was positive in 33 patients

### Table 1: Patient characteristics.

| Patient ID | Age | Sex | Regional localization | Specific localization | CK7 | CK20 | Chromo. | Sinapt. |
|------------|-----|-----|-----------------------|-----------------------|-----|------|---------|--------|
| 1          | 62  | F   | External ear          | Auricular pavilion     | −   | +    | +       | +      |
| 2          | 81  | M   | External ear          | Auricular pavilion     | −   | +    | +       | +      |
| 3          | 57  | F   | Skin face             | Eyelid                | ND  | +    | +       | +      |
| 4          | 60  | M   | Skin face             | Forehead              | +   | −    | ND      | +      |
| 5          | 64  | F   | Skin face             | Cheekbone             | −   | +    | ND      | +      |
| 6          | 65  | M   | Skin face             | Eyelid                | −   | +    | ND      | +      |
| 7          | 74  | F   | Skin face             | Cheekbone             | −   | +    | ND      | +      |
| 8          | 75  | M   | Skin face             | Cheekbone             | ND  | ND   | +       | +      |
| 9          | 76  | F   | Skin face             | Eyelid                | ND  | +    | ND      | +      |
| 10         | 77  | M   | Skin face             | Forehead              | −   | +    | ND      | +      |
| 11         | 84  | M   | Skin face             | Forehead              | ND  | +    | −       | ND      |
| 12         | 86  | M   | Skin face             | Finger                | +   | +    | ND      | +      |
| 13         | 17  | F   | Skin LLH              | Thigh                 | −   | +    | +       | +      |
| 14         | 56  | F   | Skin LLH              | Thigh                 | −   | +    | +       | +      |
| 15         | 73  | F   | Skin LLH              | Thigh                 | −   | +    | +       | +      |
| 16         | 83  | F   | Skin LLH              | Thigh                 | ND  | ND   | ND      | ND      |
| 17         | 86  | M   | Skin LLH              | Thigh                 | ND  | +    | +       | +      |
| 18         | 49  | M   | Skin NOS              | −                     | −   | +    | +       | ND      |
| 19         | 82  | M   | Skin NOS              | −                     | −   | +    | +       | ND      |
| 20         | 87  | M   | Skin NOS              | ND                    | ND  | +    | ND      | ND      |
| 21         | 72  | M   | Skin ScNk             | Neck                  | −   | +    | +       | +      |
| 22         | 86  | F   | Skin ScNk             | Scalp                 | −   | +    | +       | +      |
| 23         | 87  | M   | Skin ScNk             | Scalp                 | −   | −    | ND      | +      |
| 24         | 32  | F   | Skin UPLS             | Arm                   | −   | +    | +       | ND      |
| 25         | 61  | F   | Skin UPLS             | Arm                   | −   | +    | +       | +      |
| 26         | 69  | F   | Skin UPLS             | Arm                   | ND  | +    | +       | +      |
| 27         | 74  | F   | Skin UPLS             | Arm                   | −   | +    | ND      | +      |
| 28         | 48  | M   | UNKPO                 | −                     | −   | +    | +       | −      |
| 29         | 56  | M   | UNKPO                 | −                     | −   | +    | +       | −      |
| 30         | 64  | F   | UNKPO                 | −                     | −   | +    | +       | +      |
| 31         | 70  | M   | UNKPO                 | −                     | −   | +    | −       | ND      |
| 32         | 71  | M   | UNKPO                 | −                     | −   | −    | +       | +      |
| 33         | 71  | M   | UNKPO                 | −                     | −   | +    | +       | +      |
| 34         | 71  | M   | UNKPO                 | −                     | −   | +    | +       | +      |
| 35         | 76  | M   | UNKPO                 | −                     | −   | +    | +       | +      |
| 36         | 81  | F   | UNKPO                 | −                     | ND  | −    | +       | +      |

UNKPO, unknown primary origin; skin NOS, skin not otherwise specified; skin UPLS, skin, upper limb, and shoulder; skin LLH, skin, lower limb, and hip; skin ScNk, skin, scalp, and neck; ND, no data.
chromogranin A was positive in 25 patients (83.3%), and synaptophysin was positive in 24 patients (96.0%).

We analyzed the localization by sex (Tables 2 and 3), and it showed that unknown primary site was 2 (12.5%) in female and 7 (35%) in male, skin without specification was 0 in women and 3 (8.3%) in men, head and neck localization was 6 (37.5%) in women and 9 (45%) in men; upper limb 4 (25%) in women and 0 in men, and lower limb in women was 4 (25%) and 1 (5%) in men. Figure 2 shows the distribution of localization by sex. We match the CK-20 results with neuroendocrine markers; CK-20 was positive in 30 of the neuroendocrine markers (93.8%), and 2 CK-20 positive were negative for neuroendocrine markers. 2 samples negative for CK-20 were positive for neuroendocrine markers and one sample did not have CK-20 result.

4. Discussion

Merkel cell carcinoma is a rare skin tumor and its diagnosis is difficult. The diagnosis of Merkel cell carcinoma is confirmed with immunohistochemical stains for distinction from other small-cell malignancies, as small-cell lung cancer, melanoma, or lymphoma. CK-20 is a marker for MCC and is found positive in 89–100% of cases, other neuroendocrine markers that are used to support the diagnosis of MCC are synaptophysin and chromogranin, and others are positively stained by MCC [10]. This series of cases shows the experience of Merkel diagnosis in 16 years in a reference center of pathology.

This review shows the clinical presentation and the confirmatory immunohistochemical stains (Table 4) to differentiate from other neuroendocrine tumors. From this analysis, the head and neck were the most common localization, followed by primary site unknown, and this review similar to others reports of Hitchcock et al. who reported primary site lesion as head and neck 48.9%, upper
extremities 15.6%, and lower extremities 30.2%, but without report of the unknown primary site [11]. Heath et al. reported the unknown primary site in 14% of 195 cases similar to this study [5], which is less in limbs due to reports of skin without other specifications in our study.

This review of 37 cases of diagnosis of MCC also showed a trend in limb localization for women, especially in lower limbs. 25% in upper limb and lower limb in women and 0% and 5%, respectively, in men. It differs from the study by Agelli et al. that reported similar presentations in limbs by sex in males (20.6% upper limbs and 17.5% lower limbs) and females (17.5% in upper limbs and 14.4% in lower limbs) [9]. These gender differences are not well explained in this study; we hypothesized that these differences could be possible due to exposure of limbs to sunlight in women in tropical countries because of wearing skirts. The association of gender and upper limbs are described in melanoma studies. Guiasvand et al. reported a stronger risk factor for melanoma on lower limbs (RR 3.38; 95% CI, 2.62–4.38) in Norwegian women [12]. Another explanation could be the relationship between positive MCPyV in female patients which is more prevalent than in male patients (66.7% vs 39.6) and MCPyV and MCC are more common in limbs [13]. However, there is not enough available information in Latin American countries to explain this finding.

Disclosure

This report was presented as a poster at the 31st European Congress of Pathology in Nice, France.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

[1] P. W. Harms, On behalf of the International Workshop on Merkel Cell Carcinoma Research (IWMCC) Working Group, K. L. Harms et al., “The biology and treatment of Merkel cell carcinoma: current understanding and research priorities,” Nature Reviews Clinical Oncology, vol. 15, no. 12, pp. 763–776, 2018.
[2] T. L. Fitzgerald, S. Dennis, S. D. Kachare, N. A. Vohra, J. H. Wong, and E. E. Zervos, “Dramatic increase in the incidence and mortality from Merkel cell carcinoma in the United States,” The American Surgeon, vol. 81, no. 8, pp. 802–806, 2015.
[3] C. Carneiro, J. C. Sbalchiero, B. R. Caiado Neto, G. B. Graziosi, and F. D. P. Dumas, “Carcinoma de células de Merkel: apresentação clínica, fatores prognósticos, tratamento e sobrevida de 32 pacientes,” Revista Brasileira de Cirurgia Plástica, vol. 28, no. 2, pp. 196–200, 2013.
[4] H. G. Skelton, K. J. Smith, C. L. Hitchcock, W. F. McCarthy, G. P. Lupton, and J. H. Graham, “Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival,” Journal of the American Academy of Dermatology, vol. 37, no. 5, pp. 734–739, 1997.
[5] M. Heath, N. Jaimes, B. Lemos et al., “Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features,” Journal of the American Academy of Dermatology, vol. 58, no. 3, pp. 375–381, 2008.
[6] T. Amaral, U. Leiter, and C. Garbe, “Merkel cell carcinoma: epidemiology, pathogenesis, diagnosis and therapy,” Reviews in Endocrine and Metabolic Disorders, vol. 18, no. 4, pp. 517–532, 2017.
[7] D. Schadendorf, C. Lebbé, A. zur Hausen et al., “Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs,” European Journal of Cancer, vol. 71, pp. 53–69, 2017.
[8] S. Q. Wong, K. Waldeck, I. A. Vergara et al., “UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas,” Cancer Research, vol. 75, no. 24, pp. 5228–5234, 2015.
[9] K. Coggshall, T. L. Tello, J. P. North, and S. S. Yu, “Merkel cell carcinoma: an update and review,” Journal of the American Academy of Dermatology, vol. 78, no. 3, pp. 433–442, 2018.
[10] Y. A. Ghouri, S. G. Krishna, U. R. Kundu, M. S. Butani, J. H. Lee, and W. A. Ross, “A case series and literature review of Merkel cell carcinoma metastasizing to pancreas,” Digestive Diseases and Sciences, vol. 60, no. 6, pp. 1805–1812, 2015.
[11] C. L. Hitchcock, K. I. Bland, R. G. Laney, D. Franzini, B. Harris, and E. M. Copeland, “Neuroendocrine (Merkel cell) carcinoma of the skin,” Annals of Surgery, vol. 207, no. 2, pp. 201–207, 1988.
[12] R. Ghiasvand, T. E. Robsahm, A. C. Green et al., “Association of phenotypic characteristics and UV radiation exposure with risk of melanoma on different body sites,” JAMA Dermatology, vol. 155, no. 1, pp. 39–49, 2019.
[13] L. Wang, P. W. Harms, N. Palanisamy et al., “Age and gender associations of virus positivity in Merkel cell carcinoma characterized using a novel RNA in situ hybridization assay,” Clinical Cancer Research, vol. 23, no. 18, pp. 5622–5630, 2017.

Table 4: Neuroendocrine markers vs. CK-20 status.

| Neuroendocrine markers | CK-20 Negative | CK-20 Positive |
|------------------------|----------------|---------------|
| Negative               | 0              | 2 (6.2%)      |
| Positive               | 2 (100%)       | 30 (93.8%)    |
| Total                  | 2              | 32            |